European Union - English - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - idebenone - optic atrophy, hereditary, leber - other psychostimulants and nootropics, psychoanaleptics, - raxone is indicated for the treatment of visual impairment in adolescent and adult patients with leber’s hereditary optic neuropathy (lhon).

United Kingdom - English - myHealthbox

chiesi limited - beclometasone dipropionate, formoterol fumarate dihydrate. - pressurised inhalation solution. - 200/6 micrograms/metered dose - drugs for obstructive airway diseases; adrenergics, inhalants - fostair is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist or - patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists. fostair is indicated in adults.

European Union - English - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - deferiprone - beta-thalassemia; iron overload - all other therapeutic products - ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.

European Union - English - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - cangrelor - acute coronary syndrome; vascular surgical procedures - antithrombotic agents - kengrexal, co-administered with acetylsalicylic acid (asa), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (pci) who have not received an oral p2y12 inhibitor prior to the pci procedure and in whom oral therapy with p2y12 inhibitors is not feasible or desirable.

European Union - English - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - mercaptamine bitartrate - cystinosis - other alimentary tract and metabolism products, - procysbi is indicated for the treatment of proven nephropathic cystinosis. cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.

European Union - English - EMA (European Medicines Agency)

chiesi farmaceutici spa - caffeine citrate - apnea - psychoanaleptics, - treatment of primary apnoea of premature newborns.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - mannitol - inhalation powder - 40mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - mannitol - inhalation powder - 40mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - caffeine citrate - solution for infusion - 20mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - tacrolimus monohydrate - modified-release tablet - 1mg